BioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancer

Corporate Breaking News

Home : BioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancer

Apr 12 2021	BioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancer
LUND, Sweden, April 12, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that Oncurious NV has presented data from a phase I dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB) at the...


Source:https://www.prnewswire.com:443/news-releases/bioinvents-partner-oncurious-nv-presents-phase-i-data-on-tb-403-in-pediatric-cancer-301266424.html

Related News
» Walmart China and Dada Group's JDDJ Expand Collaboration on Omni-Channel Customer Digitalization » Hand Sanitizer Market in India Analysis and Forecast Report 2021-2025 with Q1,2021 COVID-19 Impact Update\|Technavio